Zymar
(gatifloxacin)ApprovedSmall molecule
AbbVieZymar is one of 53 small molecule programs targeting Cataract. It is currently in Approved.
2
Indications
11
Total Trials
0
Active Trials
52
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
61 competitors in Cataract
#DrugCompanyPhaseTrials
1Avelox
BayerApproved
Eylea
RegeneronApproved
Decadron
AAspen Global Incorporated
Approved
Bromday
BBausch Health Americas, Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Lovenox
SanofiApproved
Toradol
RocheApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Cipro
BayerApproved
Voltaren
NovartisApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Concentration2 trials
Cataract2 trials
Bacterial Conjunctivitis2 trials
Fluoroquinolone1 trial
3 more indications
Pulmonary Tuberculosis1 trial
Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00396084·70 enrolled
Regulatory
FDA Approval Timeline[4]
Mar 28, 2003
ZYMAR
NDA NDA021493
May 18, 2010
ZYMAXID
NDA NDA022548
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for gatifloxacin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]